MDXH
vs
S&P 500

Over the past 5 years, MDXH has underperformed S&P 500, delivering a return of -78% compared to the S&P 500's 81% growth.

Stocks Performance
MDXH vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Performance Gap
MDXH vs S&P 500

Performance Comparison
MDXH vs S&P 500

1 Month 3 Months 6 Months 1 Year 5 Years 10 Years 20 Years
MDXH
MDxHealth SA
20%
18%
4%
-43%
-78%
-96%
-97%
S&P 500
Market Index
-3%
3%
7%
24%
81%
186%
389%

MDxHealth SA
Glance View

Market Cap
117.3m USD
Industry
Biotechnology

MDxHealth SA engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

MDXH Intrinsic Value
9.06 USD
Undervaluation 74%
Intrinsic Value
Price
M

See Also

Back to Top